The economic burden of psoriasis: a systematic literature review

Abstract

Costs associated with psoriasis present a considerable economic burden. A previously published review was lacking comprehensive data on biologics. Therefore, a systematic literature review was performed to gain a comprehensive understanding of the economic burden of psoriasis throughout the world. Studies published in the English language between January 2001 and May 2013 reporting the direct and indirect economic burden of psoriasis were identified from PubMed and conference proceedings. Thirty-five studies from 11 countries met the inclusion criteria. In 2004, the annual total cost (direct and indirect) in the USA alone was approximately US$1.40 billion. Among the European countries, the most recent studies reported an annual total cost per patient of €11,928 in Sweden, €8372 in Italy, €2866-6707 in Germany and CDN$7999 in Canada, based on treatment type. Costs associated with psoriasis are high in many countries, indicating a continued need for treatments that offer good value for money.

Burden of chronic urticaria relative to psoriasis in five European countries

“…Reduction in the HRQoL due to PsO is comparable with other chronic diseases such as depression, myocardial infarction, hypertension and even some cancers 21. Reported annual total cost per PsO patient was €8372 in Italy and €2866–6707 in Germany 22. PsO contributes to 0.04% of the total global DALY, which is twice the global average DALYs for acute hepatitis C 19.…”

Secukinumab significantly reduces psoriasis‐related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom

“…1 An estimated 1.3% to 2.6% of the population in the United Kingdom (UK) is affected by psoriasis. 3,4 Individuals of working age are generally affected by the disease, 5 and individuals with psoriasis are significantly more likely than those without to miss work for health-related reasons and to experience impaired productivity while at work. 3,4 Individuals of working age are generally affected by the disease, 5 and individuals with psoriasis are significantly more likely than those without to miss work for health-related reasons and to experience impaired productivity while at work.…”

Coste de la psoriasis y artritis psoriásica en cinco países de Europa: una revisión sistemática

“…La contrapartida a esta situación es que la introducción de nuevas TB podría incrementar la carga económica asociada a ambas enfermedades 2,8 . Por ello, el objetivo de este trabajo fue revisar los estudios de costes del manejo de la Ps y la APs en las 5 principales economías de Europa (Alemania, España, Francia, Italia y Reino Unido).…”